Nezve C-CAR031

C-CAR031 mushonga wekurapa weT-Cell (CAR-T) unoshandiswa neGPC3-targeting chimeric antigen receptor (CAR-T) uri kudzidzwa kuti ushandiswe pakurapa HCC.

Kufambira mberi kwekutsvagisa kweC-CAR031 mu hepatocellular carcinoma (HCC) kwakataurwa nemuromo pamusangano wepagore weAmerican Society of Clinical Oncology (ASCO) wakaitirwa muChicago muna 2024.

Nzira: Kuyedzwa kwekutanga muvanhu, kwakavhurika-label dose-escalation kunoshandisa kukurumidza titration pamwe nekugadzirwa kwei3+3. GPC3+ advanced HCC pts vakakundikana ≥ 1 line systemic treatments vakapihwa imwe iv infusion yeC-CAR031 post standard lymphodepletion. Magumo makuru kuchengetedzeka uye kushivirira, mamwe anosanganisira pharmacokinetics uye preliminary efficiency. Zviitiko zvakaipa (AEs) zvakaongororwa neCTCAE 5.0, uye cytokine release syndrome (CRS) / immune effector cell-associated neurotoxicity syndrome (ICANS) zvakaongororwa zvichienderana neASTCT 2019 criteria. Mhinduro yechinangwa yakaongororwa nemuongorori zvichienderana neRECIST 1.1.

Mhedzisiro: Kubva musi wa5 Ndira, 2024, huwandu hwemapts makumi maviri nemana hwakapihwa C-CAR031 infusion pamazinga mana edosi (DLs). Mapts ese aive neBCLC stage C HCC, 83.3% (20/24) aive ne extrahepatic metastasis. Avhareji yehuwandu hwemitsetse yekurapa yapfuura yaive 3.5 (range 1-6), 23 (95.8%) mapts akagamuchira ICIs (immune checkpoint inhibitors) uye TKIs (tyrosine kinase inhibitors). Mapts ese akaongororwa kuti aone kuchengetedzeka. Hapana chepfu inoderedza dose uye ICANS yakaonekwa. CRS yakaonekwa mu22 (91.7%) mapts ne1 (4.2%) grade (G) 3 CRS chete. Zvirwere zve ≥G3 AEs zvakajairika zvaive lymphocytopenia (100%), neutropenia (70.8%), thrombocytopenia (37.5%) uye transaminase elevation (16.7%). Chikamu chimwe chete (4.2%) chaive neG4 myelosuppression uye pt imwe (4.2%) chaive neG3 interstitial pneumonitis paDL4 yakakonzerwa neG3 CRS. MaAE ese akadzoreredzwa. Mapts 22 akaongororwa kuti anoshanda sei. Kuderera kwebundu kwakaonekwa mu90.9% pts, kwete chete muzvironda zvemukati mehepatic asiwo kune zviri kunze kwehepatic nekudzikira kwepakati kwe44.0% (range, 3.4%-94.4%). Chiyero chekutonga chirwere chaive 90.9% uye chiyero chekupindura chakanangana (ORR) chaive 50.0% yepts yeDL dzese. MuDL4, ORR yaive 57.1%.

Mhedziso: Chidzidzo ichi chakaratidza kuchengetedzeka kunogoneka uye chinokurudzira kushanda kweC-CAR031 pakurwisa bundu muvarwere vane HCC vakanyanya kurapwa.

Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.

Nhamba yefoni: 4008803716

Email：myimmnet@163.com

Mareferensi

1.https://www.prnewswire.com/news-releases/abelzeta-announces-clinical-data-showing-preliminary-anti-tumor-activity-for-c-car031-an-armored-autologous-gpc3-car-t-in-patients-with-advanced-hepatocellular-carcinoma-at-asco-annual-meeting-2024-302162941.html

2.https://www.abelzeta.com/abelzeta-announces-abstract-for-c-car031-accepted-for-presentation-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting/

3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4019

4.ASCO-2024-IR-Presentation.pdf (astrazeneca.com)